BNP Paribas Maintains Neutral on AbbVie, Raises Price Target to $247

Benzinga Newsdesk www.benzinga.com Positive 78.8%

Neg 0% Neu 0% Pos 78.8%

BNP Paribas analyst Navann Ty maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $218 to $247.